

10/508337

DT04 Rec'd PCT/PTO 20 SEP 2004

IN THE CLAIMS

This is a complete and current listing of the claims, marked with status identifiers in parentheses. The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A method for producing a drug containing composite particle, ~~being characterized by comprising the step of:~~

giving a pressure and a shearing force to a mixture, constituted of two or more kinds of powder materials including a drug powder, so as to combine the powder materials with each other.

2. (Original) The method as set forth in claim 1, wherein the mixture includes a diluting agent powder.

3. (Original) The method as set forth in claim 2, wherein the diluting agent powder is selected from a group of celluloses and starches.

4. (Currently Amended) The method as set forth in claim ~~2 or 3~~, wherein an average particle diameter of the diluting agent powder is not less than one and not more than 10000 times as large as an average particle diameter of the drug powder.

5. (Currently Amended) The method as set forth in claim ~~2-or-3~~, wherein an average particle diameter of the diluting agent powder is 1 μm or more and 5000 μm or less.

6. (Currently Amended) The method as set forth in claim ~~1-or-2~~, wherein an average particle diameter of the drug powder is 0.01 μm or more and 500 μm or less.

7. (Currently Amended) The method as set forth in claim ~~1-or-2~~, wherein a ratio at which the drug powder is contained in the drug containing composite particle is 0.01 wt % or more and 90 wt % or less.

8. (Currently Amended) The method as set forth in claim ~~1-or-2~~, wherein the drug powder is an antipyretic analgesic or an antiphlogistic.

9. (Currently Amended) A method for producing a drug containing composite particle containing a drug and a biocompatible polymer, ~~being characterized by comprising the steps of:~~

making at least one of the drug and the biocompatible polymer into a nano-particle whose average particle diameter is less than 1000 nm; and

making a mixture containing the nano particle into a composite particle in accordance with a fluid bed dry granulation method or a dry mechanical particle combining method, so as to form a polymer nano composite particle.

10. (Currently Amended) A method for producing a drug containing composite particle, ~~being characterized by comprising:~~

a primary particle formation step of forming primary particles each of which includes nano particles whose average particle diameter is less than 1000 nm; and

a combining step of combining the primary particles with each other so that the primary particles are reversibly collected, wherein a drug powder is used as the nano particles or the primary particles.

11. (Original) The method as set forth in claim 10, wherein each of the primary particles is a nano particle clump obtained by clumping a plurality of the nano particles.

12. (Currently Amended) The method as set forth in claim 10 ~~or 11~~, further comprising a nano particle formation step of forming the nano particles in accordance with spherical crystallization.

13. (Currently Amended) The method as set forth in claim

~~10-or-11~~, wherein, in the combining step, the primary particles are subjected to secondary granulation in accordance with a fluid bed dry granulation method.

14. (Original) The method as set forth in claim 13, wherein an average particle diameter of the primary particles is within a range of from 0.01 μm or more to 500 μm or less.

15. (Currently Amended) The method as set forth in claim ~~13-or-14~~, wherein a binder is used to combine the primary particles with each other in the fluid bed dry granulation method.

16. (Original) The method as set forth in claim 15, wherein the binder is an aqueous solution of a biocompatible polymer.

17. (Currently Amended) The method as set forth in claim ~~10-or-11~~, wherein, in the combining step, the primary particles are made to adhere to a surface of each of carrier particles, which are larger than the primary particles in terms of an external diameter, in accordance with a dry mechanical particle combining method.

18. (Original) The method as set forth in claim 17, wherein: an average particle diameter of the primary particles is within a range of from 0.01 μm or more to 500 μm or less, and an average

particle diameter of the carrier particles is within a range of from 1 μm or more to 500 μm or less.

19. (Currently Amended) The method as set forth in claim 17—~~or 18~~, wherein a polysaccharide powder or a hydrophilic polymer powder is used as the carrier particle.

20. (Currently Amended) The method as set forth in claim 17—~~or 18~~, further comprising a carrier particle surface modification step of modifying the surface of the carrier particle, in accordance with a fluid bed dry granulation method or the dry mechanical particle combining method, before carrying out the combining step.

21. (Original) The method as set forth in claim 20, wherein, in the carrier particle surface modification step, the surface of the carrier particle is smoothed in accordance with the fluid bed dry granulation method or the dry mechanical particle combining method, or the carrier particle is combined with lubricant particles, so as to modify the surface of the carrier particle.

22. (Currently Amended) The method as set forth in ~~any one of claims 9, 10, and 11~~, being used to produce a powdery drug which is delivered to a lung and is absorbed through the lung.

23. (Currently Amended) A method for producing a drug containing composite particle, ~~being characterized by comprising the step of:~~

-making a mixture, containing nano particles whose average particle diameter is less than 1000 nm and a drug powder whose average particle diameter is larger than the average particle diameter of the nano particles, into a composite particle in accordance with a fluid bed dry granulation method or a dry mechanical particle combining method, so as to modify a surface of the drug powder.

24. (Original) The method as set forth in claim 23, wherein a lubricant powder is used as the nano particles.

25. (Original) The method as set forth in claim 24, wherein a colloidal inorganic compound powder or a surfactant powder is used as the lubricant powder.

26. (Original) The method as set forth in claim 25, wherein the colloidal inorganic compound powder is colloidal silica.

27. (Original) The method as set forth in claim 25, wherein the surfactant powder is magnesium stearate or sugar ester.

28. (Original) The method as set forth in claim 23, wherein a polymer nano particle obtained in accordance with spherical crystallization is used as the lubricant powder.

29. (Original) The method as set forth in claim 28, wherein the polymer nano particle is constituted of a lactic acid · glycolic acid copolymer or hydroxymethyl cellulose phthalate.

30. (Currently Amended) The method as set forth in claim ~~23~~~~or~~~~24~~, wherein the average particle diameter of the drug powder is within a range of from 0.01 μm or more and 500 μm or less.

31. (Currently Amended) The method as set forth in claim ~~23~~~~or~~~~24~~, being used to produce a powdery drug which is delivered to a lung and is absorbed through the lung.

32. (New) The method as set forth in claim 3, wherein an average particle diameter of the diluting agent powder is not less than one and not more than 10000 times as large as an average particle diameter of the drug powder.

33. (New) The method as set forth in claim 3, wherein an average particle diameter of the diluting agent powder is 1 μm or more and 5000 μm or less.

34. (New) The method as set forth in claim 2, wherein an average particle diameter of the drug powder is 0.01 μm or more and 500 μm or less.

35. (New) The method as set forth in claim 2, wherein a ratio at which the drug powder is contained in the drug containing composite particle is 0.01 wt % or more and 90 wt % or less.

36. (New) The method as set forth in claim 2, wherein the drug powder is an antipyretic analgesic or an antiphlogistic.

37. (New) The method as set forth in claim 11, further comprising a nano particle formation step of forming the nano particles in accordance with spherical crystallization.

38. (New) The method as set forth in claim 11, wherein, in the combining step, the primary particles are subjected to secondary granulation in accordance with a fluid bed dry granulation method.

39. (New) The method as set forth in claim 14, wherein a binder is used to combine the primary particles with each other in the fluid bed dry granulation method.

40. (New) The method as set forth in claim 11, wherein, in the combining step, the primary particles are made to adhere to a surface of each of carrier particles, which are larger than the primary particles in terms of an external diameter, in accordance with a dry mechanical particle combining method.

41. (New) The method as set forth in claim 18, wherein a polysaccharide powder or a hydrophilic polymer powder is used as the carrier particle.

42. (New) The method as set forth in claim 18, further comprising a carrier particle surface modification step of modifying the surface of the carrier particle, in accordance with a fluid bed dry granulation method or the dry mechanical particle combining method, before carrying out the combining step.

43. (New) The method as set forth in claim 10, being used to produce a powdery drug which is delivered to a lung and is absorbed through the lung.

44. (New) The method as set forth in claim 11, being used to produce a powdery drug which is delivered to a lung and is absorbed through the lung.

45. (New) The method as set forth in claim 24,

wherein the average particle diameter of the drug powder is within a range of from 0.01 μm or more and 500 μm or less.

46. (New) The method as set forth in claim 24, being used to produce a powdery drug which is delivered to a lung and is absorbed through the lung.